|
1. Rabieian P, Zareei N, Abbaszadeh M, et al. Survey of Hematologic Markers of Influenza in Bushehr. Iran South Med J 2016; 19(5): 888-94. (Persian) 2. Paget J, Spreeuwenberg P, Charu V, et al. Global Mortality Associated With Seasonal Influenza Epidemics: New Burden Estimates And Predictors From The Glamor Project. J Glob Health 2019; 9(2): 020421. 3. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune Responses To Influenza Virus Infection. Virus Res 2011; 162(1-2): 19-30. 4. Müllbacher A, Ada G, Tha Hla R. Gamma‐ Irradiated Influenza A Virus Can Prime For A Cross‐Reactive And Cross‐Protective Immune Response Against Influenza A Viruses. Immunol Cell Biol 1988; 66(2): 153-7. 5. Babb R, Chan J, Khairat JE, et al. GammaIrradiated Influenza A Virus Provides Adjuvant Activity To A Co-Administered Poorly Immunogenic SFV Vaccine In Mice. Front Immunol 2014; 5: 267. 6. Furuya Y, Regner M, Lobigs M, et al. Effect Of Inactivation Method On The Cross-Protective Immunity Induced By Whole ‘Killed’influenza A Viruses And Commercial Vaccine Preparations. J Gen Virol 2010; 91(6): 1450-60. 7. Wilschut J, Mcelhaney J, Palache A. Rapid Reference Influenza. 2nd ed. London: Elsevier Health Sciences, 2006. 8. Babar MM, Sadaf Zaidi N, Kazi AG, et al. Virosomes-Hybrid Drug Delivery Systems. J Antivir Antiretrovir 2013; 5(7): 166-72. 9. Sercombe L, Veerati T, Moheimani F, et al. Advances And Challenges Of Liposome Assisted Drug Delivery. Front Pharmacol 2015; 6: 286. 10. Jennings GT, Bachmann MF. The Coming Of Age Of Virus-Like Particle Vaccines. Biol Chem 2008; 389(5): 521-36. 11. Kalra N, Dhanya V, Saini V, et al. Virosomes: As A Drug Delivery Carrier. Am J Adv Drug Deliv 2013; 1(1): 29-35. 12. Mischler R, Metcalfe IC. Inflexal® V a Trivalent Virosome Subunit Influenza Vaccine: Production. Vaccine 2002; 20(Suppl 5): B17-23. 13. Moser C, Amacker M, Kammer AR, et al. Influenza Virosomes As A Combined Vaccine Carrier And Adjuvant System For Prophylactic And Therapeutic Immunizations. Expert Rev Vaccines 2007; 6(5): 711-21. 14. Cusi MG. Applications Of Influenza Virosomes As A Delivery System. Hum Vaccin 2006; 2(1): 1-7. 15. Huckriede A, Bungener L, Stegmann T, et al. The Virosome Concept For Influenza Vaccines. Vaccine 2005; 23(Suppl 1): S26-38. 16. Cryz SJ, Glück R. Immunopotentiating Reconstituted Influenza Virosomes As A Novel Antigen Delivery System. Dev Biol Stand 1998; 92: 219-23. 17. González-Jara P, Fraile A, Canto T, et al. The Multiplicity Of Infection Of A Plant Virus Varies During Colonization Of Its Eukaryotic Host. J Virol 2009; 83(15): 7487-94. 18. Wickramasinghe S, Kalbfuss B, Zimmermann A, et al. Tangential Flow Microfiltration And Ultrafiltration For Human Influenza A Virus Concentration And Purification. Biotechnol Bioeng 2005; 92(2): 199-208. 19. Kalbfuss B, Genzel Y, Wolff M, et al. Harvesting And Concentration Of Human Influenza A Virus Produced In Serum‐Free Mammalian Cell Culture For The Production Of Vaccines. Biotechnol Bioeng 2007; 97(1): 73-85. 20. Killian ML. Hemagglutination Assay For Influenza Virus. In: Spackman E, editors. New York: Humana Press-Animal Influenza Virus, 2014, 3-9. 21. De Jonge J, Leenhouts JM, Holtrop M, et al. Cellular Gene Transfer Mediated By Influenza Virosomes With Encapsulated Plasmid DNA. Biochem J 2007; 405(1): 41-9. 22. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein Measurement With The Folin Phenol Reagent. J Biol Chem 1951; 193(1): 265-75. 23. Peterson GL. A Simplification Of The Protein Assay Method Of Lowry Et Al. Which Is More Generally Applicable. Anal Biochem 1977; 83(2): 346-56. 24. Mosmann T. Rapid Colorimetric Assay For Cellular Growth And Survival: Application To Proliferation And Cytotoxicity Assays. J Immunol Methods 1983; 65(1-2): 55-63. 25. Laemmli U. Most Commonly Used Discontinuous Buffer System For SDS Electrophoresis. Nature 1970; 227: 680-6. 26. Beg S, Samad A, Nazish I, et al. Colloidal Drug Delivery Systems In Vaccine Delivery. Curr Drug Targets 2013; 14(1): 123-37. 27. Schwendener RA. Liposomes As Vaccine Delivery Systems: A Review Of The Recent Advances. Ther Adv Vaccines 2014; 2(6): 159-82. 28. Paternostre M, Viard M, Meyer O, et al. Solubilization And Reconstitution Of Vesicular Stomatitis Virus Envelope Using Octylglucoside. Biophys J 1997; 72(4): 1683-94. 29. Paternostre MT, Lowy RJ, Blumenthal R. pH‐ Dependent Fusion Of Reconstituted Vesicular Stomatitis Virus Envelopes With Vero Cells Measurement By Dequenching Of Fluorescence. FEBS Lett 1989; 243(2): 251-8. 30. Mohammadzadeh Y, Gholami S, Rasouli N, et al. Introduction Of Cationic Virosome Derived From Vesicular Stomatitis Virus As A Novel Gene Delivery System For sf9 Cells. J Liposome Res 2017; 27(2): 83-9.
|
